Investigating how psilocybin affects stress-related behaviors and immune responses
Official title: A Psilocybin-Sensitive Neuroimmune Circuit Controlling Stress Behaviors
Funded at Brigham and Women's Hospital · NIH-11078869 · Data updated 2026-11-12
This study is looking at how chronic stress affects substance use disorders and whether psilocybin, a natural compound, can help by changing how our brain and immune system respond to stress, which could lead to new ways to treat these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $553,029 |
| NIH project number | 5R01DA061199-02 |
| Project ID | NIH-11078869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals experiencing substance use disorders, particularly those with a history of chronic stress.
✕Less likely to help
Patients with no history of substance use disorders or chronic stress may not receive any benefit from this research.
What this research studies
This research explores the relationship between chronic psychological stress and substance use disorders (SUDs), focusing on how psilocybin, a psychedelic compound, may help in treating these conditions. The study examines the neural circuits involved in stress and addiction, particularly the role of the 5-HT2A serotonin receptor. By understanding how psilocybin influences both the nervous and immune systems, the research aims to identify new therapeutic targets for SUDs. Patients may benefit from insights into how their stress responses can be managed through innovative treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for individuals suffering from substance use disorders and stress-related conditions.
How similar studies have gone: Previous research has shown promising results using psychedelics like psilocybin for treating mood disorders, indicating potential for success in this area as well.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Wheeler, Michael Alex — Brigham and Women's Hospital
- Study coordinator: Wheeler, Michael Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.